Therapy: Statins and liver disease: From concern to 'wonder' drugs?

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 6, 2015, Pages 320-321

  Bosch, Jaume ^a   Forns, Xavier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

CELL CYCLE ARREST; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE CYCLE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER ISCHEMIA; LIVER PROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; RISK REDUCTION; SHORT SURVEY; TREATMENT RESPONSE; VIRUS REPLICATION; FEMALE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE;

EID: 84930482185     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.78     Document Type: Short Survey

References (10)

1. Chang, C. H. et al. Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study. J. Gastroenterol. Hepatol. 30, 155-162 (2015).
2. Lewis, J. H. et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46, 1453-1463 (2007).
3. Popescu, C. I. et al. Hepatitis C virus life cycle and lipid metabolism biology. Biology (Basel) 3, 892-921 (2014).
4. Butt, A. A. et al. Effect of addition of statins to antiviral therapy in HCV infected persons: Results from ERCHIVES. Hepatology. http://dx.doi.org/10.1002/hep.27835.
5. Schaefer, E. A. & Chung, R. T. HCV and host lipids: an intimate connection. Semin. Liver Dis. 33, 358-368 (2013).
6. Zhu, Q. et al. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis. Antiviral Res. 98, 373-379 (2013).
7. Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651-1658 (2009).
8. Marrone, G. et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut http://dx.doi.org/10.1136/gutjnl-2014-308338.
9. La Mura, V. et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology 57, 1172-1181 (2013).
10. Abraldes, J. G. et al. Addition of Simvastatin to standard treatment improves survival after variceal bleeding in patients with cirrhosis. A double-blind randomized trial (NCT01095185) [abstract O167]. J. Hepatol. 6 (Suppl.), S525 (2014).